Basic information
- CAS
63-92-3- Standard SMILES
CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl- InChIKey
VBCPVIWPDJVHAN-UHFFFAOYSA-N- Molecular formula
- C18H22ClNO.ClH
- Average molar mass
- 340.3 g/mol
- Monoisotopic mass
- 339.1156697
Overview
Phenoxybenzamine Hydrochloride can cause cancer according to an independent committee of scientific and health experts.
Names & identifiers
- Preferred name
- Phenoxybenzamine Hydrochloride
- IUPAC
- N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine;hydrochloride
- English name
- Phenoxybenzamine hydrochloride
- Molecular formula
- C18H22ClNO.ClH
- Molecular weight
- 340.29
Names & synonyms
Phenoxybenzamine hydrochloride63-92-3Phenoxybenzamine HclDibenzyline chlorideDibenzyline hydrochlorideBensylyt NENPhenoxybenzamine chlorideDibenzylinDTXSID0021127NCI-C01661NSC-37448N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine hydrochloride
Show more names
PHENOXYBENZAMINEdibenzyline688ABensylytbenzylytSKF-688AdibenylinNSC 37448
2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane hydrochlorideN-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine hydrochlorideN-2-Phenoxyisopropyl-N-benzyl-chloroethylamine hydrochlorideX1IEG24OHLDTXCID701127Benzyl(2-chloroethyl)(1-methyl-2-phenoxyethyl)amine hydrochlorideNSC37448Benzylamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-, hydrochloride
Database identifiers
- CAS
63-92-3- PubChem CID
- 5284441
- DTXSID
Properties
Computed structural properties
- Topological polar surface area
- 12.5 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 2
- Rotatable bonds
- 8
- Heavy atoms
- 22
- Formal charge
- 0
- Complexity
- 262
Experimental & physicochemical properties
Solubility
less than 0.1 mg/mL at 65.3 °F (NTP, 1992)
45.8 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Melting Point280 to 284 °F (NTP, 1992)
Physical DescriptionPhenoxybenzamine hydrochloride is a white crystalline powder. Melting point 137.5-140 °C. Used as an antihypertensive drug.
Collision Cross Section194.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Physicochemical properties
- Melting point
- 137.5 °C · 137.5°C
- storage temp.
- 15 · 15-25°C
- solubility
- soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF).
- pka
- 4.4 · pKa 4.4 (Uncertain)
- form
- powder
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 42 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
H350: May cause cancer [Danger Carcinogenicity]
Hazard information
Regulatory Information
Hazard Traits - Carcinogenicity
Benzenemethanamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-, hydrochloride: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - Benzenemethanamine, N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)-, hydrochloride: Human health tier I assessment
Fire HazardsFlash point data are not available for this chemical, but it is probably combustible. (NTP, 1992)
Health HazardsSYMPTOMS: Symptoms of exposure to this compound include nasal congestion, miosis, postural hypotension, tachycardia, gastrointestinal irritation, drowsiness and fatigue.
Reactive GroupEthers
Air and Water ReactionsLight sensitive and may be sensitive to exposure to air (NTP, 1992). Insoluble in water.
Hazard Classes and Categories
Chemistry & industry
Pharmacology
FDA Pharmacological Classification
PHENOXYBENZAMINE HYDROCHLORIDE
Adrenergic alpha-Antagonists [MoA]; alpha-Adrenergic Blocker [EPC]
MeSH Pharmacological Classification
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Drugs used to cause dilation of the blood vessels.
Applications
DescriptionPhenoxybenzamine hydrochloride (dibenzyline) is an orally effective, long-acting non-selective (alpha1 and alpha2) alpha-adrenoceptor blocking agent. It is used for the control of episodes of hypertension associated withpheochromocytoma. It literally produces a "chemical sympathectomy". It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures. It has no effect on the parasympathetic system. The initialdose is 10 mg/day, increased by 10 mg every 4 days till the desired response is attained.The usual dosage range is 20-60mg/day.
UsesPhenoxybenzamine is used in treating pheochromocytoma, swelling of the medullary layer of the adrenal glands, during which a large quantity of epinephrine is produced, which leads to a significant elevation of blood pressure.
UsesPhenoxybenzamine (5.0 to 60.0 mg/day) is used in order to control episodes of hypertension and sweating, it has a relatively slow onset and prolonged effect when compared to alternative α-blockers. If tachycardia is excessive, it may also be necessary to use a betablocker concomitantly. In addition, phenoxybenzamine has been tested for its efficacy in micturition disorders resulting from neurogenic bladder, functional outlet obstruction, and partial prostatic obstruction.
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…